| review article | Q7318358 |
| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| P50 | author | Piero Olliaro | Q72250873 |
| David Sinclair | Q121248708 | ||
| Sarah Donegan | Q30111622 | ||
| Babalwa Zani | Q30111626 | ||
| Paul Garner | Q30414755 | ||
| P2860 | cites work | Effects of artemisinin derivatives on malaria transmissibility | Q48027455 |
| Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparison | Q48031726 | ||
| High efficacy of two artemisinin-based combinations (artesunate + amodiaquine and artemether + lumefantrine) in Caala, Central Angola | Q48032540 | ||
| Amodiaquine combined with sulfadoxine/pyrimethamine versus artemisinin-based combinations for the treatment of uncomplicated falciparum malaria in Africa: a meta-analysis | Q48035625 | ||
| The effects of artemether-lumefantrine vs amodiaquine-sulfalene-pyrimethamine on the hepatomegaly associated with Plasmodium falciparum malaria in children. | Q48036161 | ||
| A randomized trial of artesunate-sulfamethoxypyrazine-pyrimethamine versus artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Mali. | Q48036406 | ||
| Efficacy of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in northwest Cambodia | Q48037074 | ||
| Antimalaria studies on Qinghaosu | Q66834480 | ||
| Sulfadoxine-pyrimethamine plus artesunate versus sulfadoxine-pyrimethamine plus amodiaquine for treating uncomplicated malaria | Q24244592 | ||
| Artesunate plus mefloquine versus mefloquine for treating uncomplicated malaria | Q24245347 | ||
| Artemether-lumefantrine (six-dose regimen) for treating uncomplicated falciparum malaria | Q24245437 | ||
| Artemether-lumefantrine (four-dose regimen) for treating uncomplicated falciparum malaria | Q24246332 | ||
| Therapeutic responses to different antimalarial drugs in vivax malaria | Q24550626 | ||
| What is "quality of evidence" and why is it important to clinicians? | Q24647929 | ||
| Efficacy of two artemisinin combination therapies for uncomplicated falciparum malaria in children under 5 years, Malakal, Upper Nile, Sudan | Q24801453 | ||
| A randomized trial of artemether-lumefantrine versus mefloquine-artesunate for the treatment of uncomplicated multi-drug resistant Plasmodium falciparum on the western border of Thailand | Q24814579 | ||
| Artemisinin versus nonartemisinin combination therapy for uncomplicated malaria: randomized clinical trials from four sites in Uganda | Q24815752 | ||
| Therapeutic efficacy test in malaria falciparum in Antioquia, Colombia | Q25257833 | ||
| Cost-effectiveness study of three antimalarial drug combinations in Tanzania | Q28469054 | ||
| Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trial | Q28469217 | ||
| A randomised controlled trial to assess the efficacy of dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Peru | Q28469333 | ||
| An open label, randomised trial of artesunate+amodiaquine, artesunate+chlorproguanil-dapsone and artemether-lumefantrine for the treatment of uncomplicated malaria | Q28473004 | ||
| Open label randomized comparison of dihydroartemisinin-piperaquine and artesunate-amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in central Vietnam | Q46075114 | ||
| A randomized trial of artesunate-mefloquine versus artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Mali. | Q46266769 | ||
| High efficacy of two artemisinin-based combinations (artemether-lumefantrine and artesunate plus amodiaquine) for acute uncomplicated malaria in Ibadan, Nigeria | Q46667800 | ||
| The efficacies of artesunate-sulfadoxine-pyrimethamine and artemether-lumefantrine in the treatment of uncomplicated, Plasmodium falciparum malaria, in an area of low transmission in central Sudan | Q46897582 | ||
| A randomized open study to assess the efficacy and tolerability of dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Cambodia. | Q47825002 | ||
| Artemisinin combination therapies for treatment of uncomplicated malaria in Uganda | Q33251914 | ||
| Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison | Q33276757 | ||
| Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria | Q33279066 | ||
| Sulfadoxine-pyrimethamine-based combinations for malaria: a randomised blinded trial to compare efficacy, safety and selection of resistance in Malawi | Q33319559 | ||
| Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda | Q33342827 | ||
| Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives | Q33646966 | ||
| Randomized comparison of artemether-benflumetol and artesunate-mefloquine in treatment of multidrug-resistant falciparum malaria. | Q33690621 | ||
| Artemisinin derivatives for treating uncomplicated malaria | Q33908651 | ||
| Artemether-lumefantrine for the treatment of multidrug-resistant falciparum malaria | Q33929311 | ||
| Comparison of oral artesunate and dihydroartemisinin antimalarial bioavailabilities in acute falciparum malaria | Q34106127 | ||
| Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial | Q34413590 | ||
| Artemether-lumefantrine versus artesunate plus amodiaquine for treating uncomplicated childhood malaria in Nigeria: randomized controlled trial | Q34666104 | ||
| Artemisinin-based combination treatment of falciparum malaria. | Q34731529 | ||
| The assessment of antimalarial drug efficacy | Q34960538 | ||
| Safety and efficacy of lumefantrine-artemether (Coartem) for the treatment of uncomplicated Plasmodium falciparum malaria in Zambian adults | Q35053376 | ||
| Efficacy of three artemisinin combination therapies for the treatment of uncomplicated Plasmodium falciparum malaria in the Republic of Congo | Q35220039 | ||
| Mixed-species malaria infections in humans | Q35754421 | ||
| Efficacy of antimalarial treatment in Guinea: in vivo study of two artemisinin combination therapies in Dabola and molecular markers of resistance to sulphadoxine-pyrimethamine in N'Zérékoré | Q35791172 | ||
| Randomized clinical trial of artemisinin versus non-artemisinin combination therapy for uncomplicated falciparum malaria in Madagascar | Q35834329 | ||
| Strategies for the prevention of antimalarial drug resistance: rationale for combination chemotherapy for malaria | Q35846117 | ||
| Efficacy and tolerability of four antimalarial combinations in the treatment of uncomplicated Plasmodium falciparum malaria in Senegal | Q35891353 | ||
| A comparative study on the efficacy of artesunate plus sulphadoxine/pyrimethamine versus artemether-lumefantrine in eastern Sudan | Q35925276 | ||
| Comparative efficacy of antimalarial drugs including ACTs in the treatment of uncomplicated malaria among children under 5 years in Ghana | Q36212917 | ||
| Efficacy and safety of artemisinin-based antimalarial in the treatment of uncomplicated malaria in children in southern Tanzania | Q36372819 | ||
| Mefloquine therapy for Plasmodium falciparum malaria in children under 5 years of age in Malawi: in vivo/in vitro efficacy and correlation of drug concentration with parasitological outcome | Q36668481 | ||
| Artemisinin and the antimalarial endoperoxides: from herbal remedy to targeted chemotherapy. | Q36671618 | ||
| Amodiaquine-artesunate vs artemether-lumefantrine for uncomplicated malaria in Ghanaian children: a randomized efficacy and safety trial with one year follow-up | Q36782415 | ||
| Reduction of transmission from malaria patients by artemisinin combination therapies: a pooled analysis of six randomized trials | Q36800842 | ||
| Efficacy, safety and tolerability of artesunate-mefloquine in the treatment of uncomplicated Plasmodium falciparum malaria in four geographic zones of Nigeria | Q36889816 | ||
| A randomized trial to monitor the efficacy and effectiveness by QT-NASBA of artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment and transmission control of uncomplicated Plasmodium falciparum malaria in western Kenya | Q37010425 | ||
| A randomized trial on effectiveness of artemether-lumefantrine versus artesunate plus amodiaquine for unsupervised treatment of uncomplicated Plasmodium falciparum malaria in Ghanaian children | Q37059334 | ||
| Artemisinin-based combinations versus amodiaquine plus sulphadoxine-pyrimethamine for the treatment of uncomplicated malaria in Faladje, Mali | Q37074386 | ||
| Combination therapy for uncomplicated falciparum malaria in Ugandan children: a randomized trial | Q38397102 | ||
| Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial | Q38399521 | ||
| Combination treatments for uncomplicated falciparum malaria in Kampala, Uganda: randomised clinical trial | Q38881484 | ||
| Randomized, controlled dose-optimization studies of dihydroartemisinin-piperaquine for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand | Q38881623 | ||
| Prevention of Increasing Rates of Treatment Failure by Combining Sulfadoxine‐Pyrimethamine with Artesunate or Amodiaquine for the Sequential Treatment of Malaria | Q38882689 | ||
| Distinguishing recrudescence from reinfection in a longitudinal antimalarial drug efficacy study: comparison of results based on genotyping of msp-1, msp-2, and glurp. | Q38883375 | ||
| Sulfadoxine/pyrimethamine alone or with amodiaquine or artesunate for treatment of uncomplicated malaria: a longitudinal randomised trial | Q38883517 | ||
| A randomised trial to assess the safety and efficacy of artemether-lumefantrine (Coartem) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwanda | Q38998777 | ||
| Averting a malaria disaster | Q39118502 | ||
| An open, randomized comparison of artesunate plus mefloquine vs. dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in the Lao People's Democratic Republic (Laos). | Q39229078 | ||
| Randomized comparison of chloroquine plus sulfadoxine-pyrimethamine versus artesunate plus mefloquine versus artemether-lumefantrine in the treatment of uncomplicated falciparum malaria in the Lao People's Democratic Republic | Q39229084 | ||
| A randomized, placebo-controlled, double-blind trial on sulfadoxine-pyrimethamine alone or combined with artesunate or amodiaquine in uncomplicated malaria | Q39257146 | ||
| Amodiaquine alone, amodiaquine+sulfadoxine-pyrimethamine, amodiaquine+artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial | Q39284402 | ||
| Therapeutic efficacy of artemether-lumefantrine and artesunate-mefloquine for treatment of uncomplicated Plasmodium falciparum malaria in Luang Namtha Province, Lao People's Democratic Republic | Q39491987 | ||
| An open randomized clinical trial of Artekin vs artesunate-mefloquine in the treatment of acute uncomplicated falciparum malaria. | Q39510125 | ||
| Artesunate reduces but does not prevent posttreatment transmission of Plasmodium falciparum to Anopheles gambiae. | Q39511728 | ||
| Comparison of artemether-lumefantrine with sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in eastern Nepal. | Q39519863 | ||
| Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial | Q39532221 | ||
| An open randomized clinical trial of Artecom vs artesunate-mefloquine in the treatment of acute uncomplicated falciparum malaria in Thailand | Q39592835 | ||
| Efficacy of amodiaquine alone and combined with sulfadoxine-pyrimethamine and of sulfadoxine pyrimethamine combined with artesunate | Q39656180 | ||
| Safety and efficacy of dihydroartemisinin/piperaquine (Artekin) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan children | Q40317494 | ||
| Therapeutic efficacy and effects of artemether-lumefantrine and amodiaquine-sulfalene-pyrimethamine on gametocyte carriage in children with uncomplicated Plasmodium falciparum malaria in southwestern Nigeria. | Q40442262 | ||
| Artesunate + amodiaquine and artesunate + sulphadoxine-pyrimethamine for treatment of uncomplicated malaria in Democratic Republic of Congo: a clinical trial with determination of sulphadoxine and pyrimethamine-resistant haplotypes. | Q40469006 | ||
| A randomized, controlled study of a simple, once-daily regimen of dihydroartemisinin-piperaquine for the treatment of uncomplicated, multidrug-resistant falciparum malaria | Q40503414 | ||
| Malaria in the Nuba Mountains of Sudan: baseline genotypic resistance and efficacy of the artesunate plus sulfadoxine-pyrimethamine and artesunate plus amodiaquine combinations | Q40509311 | ||
| Efficacy of chloroquine, amodiaquine, sulphadoxine-pyrimethamine and combination therapy with artesunate in Mozambican children with non-complicated malaria. | Q40537622 | ||
| A randomized, double-blind study on the efficacy and safety of a practical three-day regimen with artesunate and mefloquine for the treatment of uncomplicated Plasmodium falciparum malaria in Africa | Q40564112 | ||
| Efficacy of six doses of artemether-lumefantrine (benflumetol) in multidrug-resistant Plasmodium falciparum malaria | Q40636345 | ||
| Efficacy of artesunate plus amodiaquine, artesunate plus sulfadoxine-pyrimethamine, and chloroquine plus sulfadoxine-pyrimethamine in patients with uncomplicated Plasmodium falciparum in the Comoros Union | Q41448475 | ||
| Efficacy of chloroquine + sulfadoxine--pyrimethamine, mefloquine + artesunate and artemether + lumefantrine combination therapies to treat Plasmodium falciparum malaria in the Chittagong Hill Tracts, Bangladesh | Q41911864 | ||
| Antimalarial efficacy of chloroquine, amodiaquine, sulfadoxine-pyrimethamine, and the combinations of amodiaquine + artesunate and sulfadoxine-pyrimethamine + artesunate in Huambo and Bie provinces, central Angola | Q41912334 | ||
| Efficacy of therapeutic combinations with artemisinin derivatives in the treatment of non complicated malaria in Burundi | Q41913929 | ||
| A trial of combination antimalarial therapies in children from Papua New Guinea. | Q41939607 | ||
| Efficacy, safety, and selection of molecular markers of drug resistance by two ACTs in Mali | Q41941272 | ||
| An open label randomized comparison of mefloquine-artesunate as separate tablets vs. a new co-formulated combination for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand | Q43601958 | ||
| A clinical and pharmacokinetic trial of six doses of artemether-lumefantrine for multidrug-resistant Plasmodium falciparum malaria in Thailand | Q43681442 | ||
| Randomized comparison of amodiaquine plus sulfadoxine-pyrimethamine, artemether-lumefantrine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Burkina Faso | Q43932437 | ||
| Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania | Q43947607 | ||
| Moderate effect of artemisinin-based combination therapy on transmission of Plasmodium falciparum | Q44167789 | ||
| Artesunate combinations for treatment of malaria: meta-analysis | Q44728450 | ||
| Efficacies of artesunate plus either sulfadoxine-pyrimethamine or amodiaquine, for the treatment of uncomplicated, Plasmodium falciparum malaria in eastern Sudan. | Q44733706 | ||
| P433 | issue | 3 | |
| P921 | main subject | artemisinin | Q426921 |
| malaria | Q12156 | ||
| P304 | page(s) | CD007483 | |
| P577 | publication date | 2009-07-08 | |
| P1433 | published in | Cochrane Database of Systematic Reviews | Q15750361 |
| P1476 | title | Artemisinin-based combination therapy for treating uncomplicated malaria |
| Q35203887 | A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania |
| Q38861043 | A randomized trial of artesunate-amodiaquine versus artemether-lumefantrine in Ghanaian paediatric sickle cell and non-sickle cell disease patients with acute uncomplicated malaria |
| Q34071772 | A study protocol for a randomised open-label clinical trial of artesunate-mefloquine versus chloroquine in patients with non-severe Plasmodium knowlesi malaria in Sabah, Malaysia (ACT KNOW trial). |
| Q17485688 | A systematic review of the safety and efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria during pregnancy |
| Q30397022 | Adherence to and acceptability of artemether-lumefantrine as first-line anti-malarial treatment: evidence from a rural community in Tanzania |
| Q36404786 | Advances in the treatment of malaria |
| Q37411702 | Antimalarial Properties of Aqueous Crude Extracts of Gynostemma pentaphyllum and Moringa oleifera Leaves in Combination with Artesunate in Plasmodium berghei-Infected Mice |
| Q24622539 | Artemisinin combination therapy for vivax malaria |
| Q35069127 | Artemisinin combination therapy: a good antimalarial, but is the dose right? |
| Q24236067 | Artemisinin-based combination therapy for the treatment of uncomplicated Plasmodium vivax malaria and the prevention of relapses |
| Q24202910 | Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria |
| Q24235351 | Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria |
| Q24235145 | Artemisinin-based combination therapy for uncomplicated P. falciparum malaria in children with HIV |
| Q26471338 | Artemisinin-based combination therapy for uncomplicatedP. falciparummalaria in children with HIV |
| Q24188020 | Artemisinin-naphthoquine for treating uncomplicated Plasmodium falciparum malaria |
| Q34084173 | Artemisone effective against murine cerebral malaria |
| Q24198103 | Artesunate plus pyronaridine for treating uncomplicated Plasmodium falciparum malaria |
| Q44432479 | Artesunate- and amodiaquine-associated extrapyramidal reactions: a series of 49 cases in VigiBase™. |
| Q43924014 | Assessing the impact of imperfect adherence to artemether-lumefantrine on malaria treatment outcomes using within-host modelling |
| Q42221020 | Assessment of the effect of larval source management and house improvement on malaria transmission when added to standard malaria control strategies in southern Malawi: study protocol for a cluster-randomised controlled trial. |
| Q34473796 | Brazilian Plasmodium falciparum isolates: investigation of candidate polymorphisms for artemisinin resistance before introduction of artemisinin-based combination therapy |
| Q37359989 | Case investigation and reactive case detection for malaria elimination in northern Senegal |
| Q30567158 | Combining individual patient data and aggregate data in mixed treatment comparison meta-analysis: Individual patient data may be beneficial if only for a subset of trials |
| Q33947834 | Comparative impacts over 5 years of artemisinin-based combination therapies on Plasmodium falciparum polymorphisms that modulate drug sensitivity in Ugandan children |
| Q33399342 | Comparing changes in haematologic parameters occurring in patients included in randomized controlled trials of artesunate-amodiaquine vs single and combination treatments of uncomplicated falciparum in sub-Saharan Africa |
| Q36507974 | Comparison of the safety and efficacy of fixed-dose combination of arterolane maleate and piperaquine phosphate with chloroquine in acute, uncomplicated Plasmodium vivax malaria: a phase III, multicentric, open-label study |
| Q35779270 | Complementary and alternative drug therapy versus science-oriented medicine |
| Q34677891 | Contrasting benefits of different artemisinin combination therapies as first-line malaria treatments using model-based cost-effectiveness analysis |
| Q34227179 | Cost-effectiveness of dihydroartemisinin-piperaquine compared with artemether-lumefantrine for treating uncomplicated malaria in children at a district hospital in Tanzania |
| Q35589032 | Costs and cost-effectiveness of malaria control interventions--a systematic review |
| Q94002417 | Curiositas (Global Health) |
| Q36876057 | Cysteamine broadly improves the anti-plasmodial activity of artemisinins against murine blood stage and cerebral malaria |
| Q34045221 | Cysteamine, the molecule used to treat cystinosis, potentiates the antimalarial efficacy of artemisinin |
| Q34737444 | Desbutyl-lumefantrine is a metabolite of lumefantrine with potent in vitro antimalarial activity that may influence artemether-lumefantrine treatment outcome. |
| Q24201077 | Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria |
| Q35226099 | Do frontline health care providers know enough about artemisinin-based combination therapy to rationally treat malaria? A cross-sectional survey in Gezira State, Sudan |
| Q61808246 | Does artemether-lumefantrine administration affect mosquito olfactory behaviour and fitness? |
| Q33874069 | Does the Use of Dihydroartemisinin-Piperaquine in Treating Patients with Uncomplicated falciparum Malaria Reduce the Risk for Recurrent New falciparum Infection More Than Artemether-Lumefantrine? |
| Q34681141 | Drug-Resistant Malaria: The Era of ACT. |
| Q42970817 | Dual protonophore-chitinase inhibitors dramatically affect O. volvulus molting |
| Q35154559 | Early variations in plasmodium falciparum dynamics in Nigerian children after treatment with two artemisinin-based combinations: implications on delayed parasite clearance |
| Q43086319 | Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial |
| Q38895510 | Efficacy and safety of artemether-lumefantrine in the treatment of acute, uncomplicated Plasmodium falciparum malaria: a pooled analysis |
| Q52609473 | Efficacy and safety of artemether-lumefantrine, artesunate-amodiaquine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in three provinces in Angola, 2017. |
| Q96126409 | Efficacy and safety of artemisinin-based combination therapy and the implications of Pfkelch13 and Pfcoronin molecular markers in treatment failure in Senegal |
| Q53702337 | Efficacy and safety of artemisinin-based combination therapy for uncomplicated Plasmodium falciparum malaria in Sudan: a systematic review and meta-analysis. |
| Q28535686 | Efficacy and safety of dihydroartemisinin-piperaquine for treatment of Plasmodium vivax malaria in endemic countries: meta-analysis of randomized controlled studies |
| Q34922694 | Efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine for treatment of uncomplicated malaria in children in Zaire and Uíge Provinces, angola |
| Q37623024 | Efficacy of artemether-lumefantrine, artesunate-amodiaquine, and dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum malaria in Angola, 2015. |
| Q28691396 | Efficacy of artesunate-amodiaquine and artemether-lumefantrine fixed-dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria among children aged six to 59 months in Nimba County, Liberia: an open-label randomized [...] |
| Q37350167 | Efficacy of artesunate-amodiaquine for treating uncomplicated falciparum malaria in sub-Saharan Africa: a multi-centre analysis |
| Q34562333 | Efficacy of quinine, artemether-lumefantrine and dihydroartemisinin-piperaquine as rescue treatment for uncomplicated malaria in Ugandan children |
| Q34177472 | Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination |
| Q30667272 | Evaluating harm associated with anti-malarial drugs: a survey of methods used by clinical researchers to elicit, assess and record participant-reported adverse events and related data. |
| Q35361412 | Evaluation of the In Vitro Efficacy of Artemisia annua, Rumex abyssinicus, and Catha edulis Forsk Extracts in Cancer and Trypanosoma brucei Cells |
| Q34114429 | Experience developing national evidence-based clinical guidelines for childhood pneumonia in a low-income setting--making the GRADE? |
| Q35108464 | Exposure to artemether-lumefantrine (Coartem) in first trimester pregnancy in an observational study in Zambia |
| Q36019224 | Expression, purification, crystallization and preliminary X-ray analysis of Plasmodium falciparum GTP:AMP phosphotransferase |
| Q35676444 | From METS to malaria: RRx-001, a multi-faceted anticancer agent with activity in cerebral malaria |
| Q35860086 | Gametocyte Clearance Kinetics Determined by Quantitative Magnetic Fractionation in Melanesian Children with Uncomplicated Malaria Treated with Artemisinin Combination Therapy |
| Q37857748 | Genetic analysis in mice identifies cysteamine as a novel partner for artemisinin in the treatment of malaria |
| Q21034164 | Global health 2035: a world converging within a generation |
| Q30557864 | Google Scholar as replacement for systematic literature searches: good relative recall and precision are not enough |
| Q36413462 | Haemoglobin changes and risk of anaemia following treatment for uncomplicated falciparum malaria in sub-Saharan Africa |
| Q24234694 | Home or community programmes for treating malaria |
| Q24202898 | Home- or community-based programmes for treating malaria |
| Q24240783 | Immunochromatography-based rapid diagnostic tests for diagnosing uncomplicated malaria in endemic countries |
| Q36018812 | Inadequate efficacy of a new formulation of fosmidomycin-clindamycin combination in Mozambican children less than three years old with uncomplicated Plasmodium falciparum malaria |
| Q48022305 | Induction of high tolerance to artemisinin by sub-lethal administration: A new in vitro model of P. falciparum. |
| Q47997750 | Intermittent preventive therapy for malaria with monthly artemether-lumefantrine for the post-discharge management of severe anaemia in children aged 4-59 months in southern Malawi: a multicentre, randomised, placebo-controlled trial. |
| Q28481649 | Intermittent preventive treatment for malaria in Papua New Guinean infants exposed to Plasmodium falciparum and P. vivax: a randomized controlled trial |
| Q91935137 | Investigating the Comparative Effects of Six Artemisinin-based Combination Therapies on Plasmodium-induced Hepatorenal Toxicity |
| Q94397801 | Ivermectin treatment in humans for reducing malaria transmission |
| Q24201852 | Larvivorous fish for preventing malaria transmission |
| Q46244064 | Larvivorous fish for preventing malaria transmission. |
| Q30044965 | Longitudinal genomic surveillance of Plasmodium falciparum malaria parasites reveals complex genomic architecture of emerging artemisinin resistance |
| Q35941421 | MK-4815, a potential new oral agent for treatment of malaria |
| Q58609032 | Malaria chemoprevention with monthly dihydroartemisinin-piperaquine for the post-discharge management of severe anaemia in children aged less than 5 years in Uganda and Kenya: study protocol for a multi-centre, two-arm, randomised, placebo-controlled |
| Q34832467 | Malaria diagnostic testing and treatment practices in three different Plasmodium falciparum transmission settings in Tanzania: before and after a government policy change |
| Q52704614 | Malaria in children. |
| Q40081071 | Modelling the benefits of long-acting or transmission-blocking drugs for reducing Plasmodium falciparum transmission by case management or by mass treatment |
| Q64257418 | Monitoring the Efficacy and Safety of Artemisinin-Based Combination Therapies: A Review and Network Meta-analysis of Antimalarial Therapeutic Efficacy Trials in Cameroon |
| Q36394490 | Multiple treatment comparisons in a series of anti-malarial trials with an ordinal primary outcome and repeated treatment evaluations |
| Q36969682 | Nonrandomized controlled trial of artesunate plus sulfadoxine-pyrimethamine with or without primaquine for preventing posttreatment circulation of Plasmodium falciparum gametocytes |
| Q52881142 | Optimal control of malaria: combining vector interventions and drug therapies. |
| Q37396457 | Optimal price subsidies for appropriate malaria testing and treatment behaviour |
| Q56336555 | Optimization and evaluation of lipid emulsions for intravenous co-delivery of artemether and lumefantrine in severe malaria treatment |
| Q34129977 | PXR variants and artemisinin use in Vietnamese subjects: frequency distribution and impact on the interindividual variability of CYP3A induction by artemisinin |
| Q37703517 | Plasmodium falciparum clearance in clinical studies of artesunate-amodiaquine and comparator treatments in sub-Saharan Africa, 1999-2009 |
| Q34281680 | Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine |
| Q36306811 | Population coverage of artemisinin-based combination treatment in children younger than 5 years with fever and Plasmodium falciparum infection in Africa, 2003-2015: a modelling study using data from national surveys |
| Q35590734 | Population-wide malaria testing and treatment with rapid diagnostic tests and artemether-lumefantrine in southern Zambia: a community randomized step-wedge control trial design |
| Q36328321 | Post-licensure safety evaluation of dihydroartemisinin piperaquine in the three major ecological zones across Ghana |
| Q36840090 | Prevalence of molecular markers of drug resistance in an area of seasonal malaria chemoprevention in children in Senegal |
| Q38974989 | Profile of adverse events in patients receiving treatment for malaria in urban Ghana: A cohort-event monitoring study |
| Q36086864 | Prospective evaluation of artemether-lumefantrine for the treatment of non-falciparum and mixed-species malaria in Gabon |
| Q33875677 | Protective efficacy of malaria case management and intermittent preventive treatment for preventing malaria mortality in children: a systematic review for the Lives Saved Tool |
| Q26743363 | Psychiatric effects of malaria and anti-malarial drugs: historical and modern perspectives |
| Q61800665 | Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria |
| Q30499150 | Randomized controlled trials of malaria intervention trials in Africa, 1948 to 2007: a descriptive analysis |
| Q21032516 | Rapid diagnostic tests for diagnosing uncomplicated P. falciparum malaria in endemic countries |
| Q28487881 | Reduced susceptibility of Plasmodium falciparum to artesunate in southern Myanmar |
| Q33898575 | Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs |
| Q49790353 | Rocaglates as dual-targeting agents for experimental cerebral malaria |
| Q30396615 | SMS for Life: a pilot project to improve anti-malarial drug supply management in rural Tanzania using standard technology |
| Q90135493 | Safety and tolerability of artesunate-amodiaquine, artemether-lumefantrine and quinine plus clindamycin in the treatment of uncomplicated Plasmodium falciparum malaria in Kinshasa, the Democratic Republic of the Congo |
| Q36483387 | Safety of falciparum malaria diagnostic strategy based on rapid diagnostic tests in returning travellers and migrants: a retrospective study |
| Q48021707 | Safety of single low-dose primaquine in glucose-6-phosphate dehydrogenase deficient falciparum-infected African males: Two open-label, randomized, safety trials |
| Q37607325 | Safety, tolerability, and efficacy of repeated doses of dihydroartemisinin-piperaquine for prevention and treatment of malaria: a systematic review and meta-analysis |
| Q90369639 | Significant efficacy of single low dose primaquine compared to stand alone artemisinin combination therapy in reducing gametocyte carriage in Cambodian patients with uncomplicated multidrug resistant Plasmodium falciparum malaria |
| Q47553004 | Study protocol for a cluster randomised controlled factorial design trial to assess the effectiveness and feasibility of reactive focal mass drug administration and vector control to reduce malaria transmission in the low endemic setting of Namibia |
| Q24202924 | Subsidising artemisinin-based combination therapies supplied to the private sector: impact on use, availability, price and market share |
| Q34518266 | Systematic reviews need to consider applicability to disadvantaged populations: inter-rater agreement for a health equity plausibility algorithm |
| Q38891868 | Tacrolimus prevents murine cerebral malaria |
| Q38840716 | The Relative Effects of Artemether-lumefantrine and Non-artemisinin Antimalarials on Gametocyte Carriage and Transmission of Plasmodium falciparum: A Systematic Review and Meta-analysis |
| Q26315552 | The Validity of Rapid Malaria Test and Microscopy in Detecting Malaria in a Preelimination Region of Egypt |
| Q26822489 | The effect of dosing regimens on the antimalarial efficacy of dihydroartemisinin-piperaquine: a pooled analysis of individual patient data |
| Q30936416 | The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data |
| Q36471393 | The novel ETA receptor antagonist HJP-272 prevents cerebral microvascular hemorrhage in cerebral malaria and synergistically improves survival in combination with an artemisinin derivative |
| Q28478260 | The potential contribution of mass treatment to the control of Plasmodium falciparum malaria |
| Q28478579 | The use of artemether-lumefantrine for the treatment of uncomplicated Plasmodium vivax malaria |
| Q35031900 | Therapeutic efficacies of artemisinin-based combination therapies in Nigerian children with uncomplicated falciparum malaria during five years of adoption as first-line treatments |
| Q97524546 | Therapeutic efficacy of artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Chewaka District, Ethiopia |
| Q33880614 | Tolerability and efficacy of a pediatric granule formulation of artesunate-mefloquine in young children from Cameroon with uncomplicated falciparum malaria |
| Q28691509 | Tolerability and safety of artesunate-amodiaquine and artemether-lumefantrine fixed dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria: two open-label, randomized trials in Nimba County, Liberia |
| Q35004430 | Treating uncomplicated malaria in children: comparing artemisinin-based combination therapies |
| Q35494944 | Treatment of Febrile illness with artemisinin combination therapy: prevalence and predictors in five African household surveys |
| Q38907878 | UK malaria treatment guidelines 2016. |
Search more.